{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:26:06Z","timestamp":1784611566893,"version":"3.55.0"},"reference-count":91,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2005,5,13]],"date-time":"2005-05-13T00:00:00Z","timestamp":1115942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["faseb.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The FASEB Journal"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Endocannabinoids and cannabinoid CB1 receptors play a role in the control of movement by modulating GABA, glutamate, and other neurotransmitters throughout the basal ganglia. Roles for abnormalities in endocannabinoid signaling in Parkinson's disease (PD) and the major side effect of current treatments, levodopa\u2010induced dyskinesia (LID), have been suggested by rodent studies. Here we show that signaling by endocannabinoids contributes to the pathophysiology of parkinsonism and LID in MPTP\u2010lesioned, non\u2010human primate models of Parkinson's disease. In MPTP\u2010lesioned marmosets previously treated with levodopa to establish LID, attenuation of CB1 signaling by systemic administration of rimonabant (1 and 3 mg\/kg) had anti\u2010parkinsonian actions, equivalent to a 71% increase in motor activity at 3 mg\/kg. Rimonabant did not elicit dyskinesia. Co\u2010administration of levodopa (8 mg\/kg) and rimonabant (1 and 3 mg\/kg) resulted in significantly less dyskinesia than levodopa alone, without significantly affecting the anti\u2010parkinsonian action of levodopa. These data suggest that enhanced endocannabinoid signaling may be involved in the pathophysiology of both parkinsonism and LID. To define potential mechanisms by which such a role might be mediated, we determined the levels of the endocannabinoids anandamide and 2\u2010arachidonyl glycerol (2\u2010AG) throughout the basal ganglia in normal and three groups of MPTP\u2010lesioned cynomolgus monkeys (untreated; acutely treated with L\u2010DOPA, non\u2010dyskinetic; long\u2010term treated, with levodopa\u2010induced dyskinesia). In the untreated, MPTP\u2010lesioned primate, parkinsonism was associated with increases in both 2\u2010AG (+88%) and anandamide (+49%) in the striatum, and of 2\u2010AG (+97%) in the substantia nigra, changes that are consistent with the previously suggested role for endocannabinoids in mechanisms attempting to compensate for loss of dopamine in untreated parkinsonism. Increased levels of anandamide (+34%) in the external globus pallidus of MPTP\u2010lesioned animals were normalized by levodopa treatment and may contribute to the generation of parkinsonian symptoms. However, no clear alteration in endocannabinoid levels could be correlated with the expression of LID. These data highlight the potential roles played by endocannabinoids and CB1 in PD and LID and suggest the need for further research to pursue the multiple therapeutic opportunities for manipulating this system in movement disorders.<\/jats:p>","DOI":"10.1096\/fj.04-3010fje","type":"journal-article","created":{"date-parts":[[2005,5,13]],"date-time":"2005-05-13T20:15:10Z","timestamp":1116015310000},"page":"1140-1142","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":174,"title":["A role for endocannabinoids in the generation of parkinsonism and levodopa\u2010induced dyskinesia in MPTP\u2010lesioned non\u2010human primate models of Parkinson's disease"],"prefix":"10.1096","volume":"19","author":[{"given":"Mario","family":"van der Stelt","sequence":"first","affiliation":[{"name":"Endocannabinoid Research Group Istituto di Chimica Biomolecolare Consiglio Nazionale delle Ricerche  Pozzuoli (NA) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[{"name":"Movement Disorders Clinic Toronto Western Hospital  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hill","sequence":"additional","affiliation":[{"name":"Division of Neuroscience School of Biological Sciences University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Crossman","sequence":"additional","affiliation":[{"name":"Division of Neuroscience School of Biological Sciences University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Petrosino","sequence":"additional","affiliation":[{"name":"Endocannabinoid Research Group Istituto di Chimica Biomolecolare Consiglio Nazionale delle Ricerche  Pozzuoli (NA) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Marzo","sequence":"additional","affiliation":[{"name":"Endocannabinoid Research Group Istituto di Chimica Biomolecolare Consiglio Nazionale delle Ricerche  Pozzuoli (NA) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[{"name":"Toronto Western Research Institute Toronto Western Hospital  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,5,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.2.340"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10031"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.9.1687"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.10513","article-title":"Limitations of current Parkinson's disease therapy","volume":"53","author":"Rascol O.","year":"2003","journal-title":"Ann. Neurol."},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/WNL.61.6_suppl_3.S24","article-title":"Present and future directions in the management of motor complications in patients with advanced PD","volume":"61","author":"Olanow C. W.","year":"2003","journal-title":"Neurology"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050203"},{"key":"e_1_2_6_9_1","first-page":"S22","article-title":"Pathophysiology of levodopa\u2010induced dyskinesias in Parkinson's disease: problems with the current model","volume":"47","author":"Obeso J. A.","year":"2000","journal-title":"Ann. Neurol."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/35086062"},{"key":"e_1_2_6_11_1","unstructured":"Brotchie J. M. Lee J. andVenderova K.(2004)L\u2010DOPA\u2010induced dyskinesia.J. Neural Transm.In press"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(03)00038-9"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.01759.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1997.77.3.1635"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)01475-3"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199801)28:1<27::AID-SYN4>3.0.CO;2-E"},{"key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0163-7258(88)90106-4","article-title":"The central neuropharmacology of psychotropic cannabinoids","volume":"36","author":"Pertwee R. G.","year":"1998","journal-title":"Pharmacol. Thera."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1997.tb01390.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(02)00253-X"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03033228"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/7268"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.08.101"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(02)00011-5"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.14.10.1432"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.5.1932"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2001.85.1.468"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-35-11073.2003"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00012-0"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00509-7"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0731084.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90970-7"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-001-0520-z"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)01117-X"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00109-4"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(00)00036-1"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00326-3"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(91)90150-A"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100728"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6645"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10289"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10312"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02477-9"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0773.2003.930202.x"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2003.02896.x"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.11.2108"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207458608985678"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-25028"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300407"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2001.7649"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(99)00762-4"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(99)00618-9"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0953-816x.2001.01812.x"},{"key":"e_1_2_6_55_1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0022-3565(25)12911-X","article-title":"In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9\u2010tetrahydrocannabinol\u2010induced responses and apparent agonist activity","volume":"277","author":"Compton D. R.","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2001.7727"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100606"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.03.022"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.05.004"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.062414"},{"key":"e_1_2_6_62_1","first-page":"171","article-title":"Levetiracetam (Keppra) interferes with the L\u2010DOPA priming process in MPTP\u2010lesioned drug naive marmosets","volume":"27","author":"Hill M. P.","year":"2004","journal-title":"Clin. Pharmacol."},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.066191"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10464"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10542"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1148"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/35071088"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(200001)35:1<8::AID-SYN2>3.0.CO;2-Y"},{"key":"e_1_2_6_70_1","first-page":"1103","article-title":"SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists","volume":"20","author":"Costa B.","year":"1999","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7444"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7374"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.01.018"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90646-Y"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1985.tb07205.x"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870010102"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)91545-C"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(89)90120-6"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)90762-Z"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1994.1007"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10343"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199604)22:4<382::AID-SYN9>3.0.CO;2-7"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410430415"},{"key":"e_1_2_6_84_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2001.7763"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870060404"},{"key":"e_1_2_6_86_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2402638"},{"key":"e_1_2_6_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130603"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530210109030"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10107"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1280"},{"key":"e_1_2_6_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200405000-00003"}],"container-title":["The FASEB Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fj.04-3010fje","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1096\/fj.04-3010fje","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fj.04-3010fje","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:20:13Z","timestamp":1761700813000},"score":1,"resource":{"primary":{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/10.1096\/fj.04-3010fje"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,13]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1096\/fj.04-3010fje"],"URL":"https:\/\/doi.org\/10.1096\/fj.04-3010fje","archive":["Portico"],"relation":{},"ISSN":["0892-6638","1530-6860"],"issn-type":[{"value":"0892-6638","type":"print"},{"value":"1530-6860","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,13]]},"assertion":[{"value":"2004-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}